$DMAC insider trading
Over the last 12 months, DiaMedica Therapeutics insiders reported 2 buys totaling $13.6M and no sales across SEC Form 4 filings.
- Bought · 12m
- $13.6M 2 events
- Sold · 12m
- — 0 events
- Events · 12m
- 2 Form 4 filings, grouped
- Insiders · 12m
- 1 distinct reporters
- 10b5-1 share
- 0% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Nov 25, 2025 | STAHLBERG JAN10% | ▲ Buy | 1,061,277 | $7.19 | $7.6M | +13.7% | late · 7 tranches · indirect |
| Aug 27, 2025 | STAHLBERG JAN10% | ▲ Buy | 1,000,000 | $5.96 | $6.0M | +14.8% | late · 9 tranches · indirect |
Get an alert the next time a $DMAC insider files
Form 4 filings land on this page within minutes of hitting EDGAR. A free account turns that into an email whenever DiaMedica Therapeutics insiders buy or sell, with the plan flag and the dollar value already read.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $DMAC feed.